Oratec Interventions Inc.
Arthroscopy systems and minimally-invasive treatments for lower back
You may also be interested in...
The Italian firm's move to license Isturisa from Novartis last year is paying dividends already and Recordati has already tripled its peak sales forecast for the Cushing's therapy.
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-two guidance documents have been posted on the tracker since its last update.